[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"clonal-hematopoiesis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:clonal-hematopoiesis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,73,98,127,155,186,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100637222","a-dietary-study-for-people-with-clonal-hematopoiesis-100637222",false,"NCT07590804","A Dietary Study for People With Clonal Hematopoiesis","A Decentralized High-Fiber Dietary Intervention Trial in Clonal Hematopoiesis - NUTRIVENTION-CH","Inclusion Criteria:\n\n* Patients must have confirmed clonal hematopoiesis via next generation sequencing (NGS) of blood or bone marrow biopsy sample\n* Patients with clonal cytopenias of undetermined significance (CCUS) are eligible if a bone marrow biopsy is done to exclude other causes.\n* Variant allele frequency must be ≥2% for mutation as measured by (NGS)\n* Treatment at MSK or at sites listed below that uses EPIC for electronic medical records and willing to share records with MSK through EPIC's care everywhere or through MSK's shared care network. If not meeting this criterion, decision to allow for participation is per PI discretion.\n* Age ≥ 18 years\n* BMI ≥25 kg\u002Fm\\^2\n* Participant or caregiver must be able to complete surveys and have interest in trying new recipes or cooking.\n* Screening 24-hour dietary recall must consume \\\u003C30 grams dietary fiber per day to be eligible (any one of two 24-hour screening dietary recalls).\n* For patients at MSK, require bone marrow biopsy at screening in the past 24 weeks with collection of research biobanking sample. Bone marrow at other sites is optional.\n\nExclusion Criteria:\n\n* Prior MDS\u002FAML directed therapy\n* Chemotherapy, radiation, or immunotherapy within the past year (surgical- resection only or other cancer\u002Fprecancer on observation is eligible)\n* Patients with a concurrent malignancy whose natural history or treatment may compromise completion of this trial are excluded.\n* Concurrent pregnancy will make a participant ineligible to participate\n* Patients that already follow a minimally processed (whole food) plant-based diet in the last 3 months are not eligible (ovo-lacto-vegetarian or processed junk food vegan diets are eligible).\n* Patients on GLP-1 drugs are eligible if it has been started at least 3 months prior to study and on stable dose. If it has been started more recently for diabetes mellitus control but not weight loss they are eligible. If it is medically indicated and started for diabetes mellitus control while on trial they will not be removed\u002Fexcluded from trial.\n* Mental impairment leading to inability to cooperate will lead to exclusion from trial participation.\n* If in the opinion of the investigator there maybe any concerns regarding the ability of the patient to complete the study safely or any contraindications.\n* Concurrent weight loss or dietary programs will be ineligible if require a specific diet or weight loss supplements.\n* Plan for prolonged travel during the study that would preclude adherence to prescribed diet. Willingness to comply during travel is not an exclusion.\n* Severe allergy to any legume (such as anaphylactic shock) or allergies to multiple legumes or if cross-contamination is a risk are not eligible.\n* Severe allergies such as anaphylactic shock to peanuts and\u002For tree nuts, such as cashews are not eligible.","ALL","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"NA","The researchers are doing this study to find out whether a high-fiber plant-based diet (HFPBD) can improve quality of life for people with CH. A HFPBD includes foods that are mainly from plants (for example, fruits,vegetables, nuts, beans, and whole grains). The researchers will measure quality of life by having participants complete questionnaires\u002Fsurveys.",[26],"Clonal Hematopoiesis",[28],"High-Fiber Plant Diet","RECRUITING","2026-05-12",{"date":32,"type":33},"2026-05-15","ACTUAL",{"date":35,"type":33},"2026-05-04",{"date":37,"type":20},"2027-05",{"name":39,"class":40},"Memorial Sloan Kettering Cancer Center","OTHER",7,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100617010","chapter-clonal-haematopoiesis-assessment-prevention-treatment-and-research-100617010","NCT07313059","CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research","Prospective Clinical Evaluation of Incidence, Outcomes and Individuals Experiences Following Diagnosis of Clonal Haematopoiesis in a Dedicated Research Clinic","CHAPTER","Inclusion Criteria:\n\n1. Aged 55 years and above\n2. Confirmed CH or possible CH, with possible CH defined by:\n\n   a. Persistent, non-severe cytopenia, characterised by one or more of the following, present on at least 2 occasions, at least 4 months apart (WHO criteria): i. Absolute neutrophil count (ANC) \\\u003C 1.8 x 109\u002FL ii. Haemoglobin (Hb) \\\u003C 120 g\u002FL in females, \\\u003C 130 g\u002FL in males iii. Platelet count \\\u003C 150 x 109\u002FL\n3. Provision of written informed consent prior to any study-related assessments or procedures being carried out.\n\nExclusion Criteria:\n\n1. Severe cytopenia as defined by one or more of the following:\n\n   1. ANC \\\u003C 0.5 x109\u002FL\n   2. Hb \\\u003C 80 g\u002FL\n   3. Platelet count \\\u003C 50 x 109\u002FL\n2. Multilineage cytopenias:\n\n   a. Marked trilineage cytopenia with all the following present: i. ANC \\\u003C 1.0 x 109\u002FL AND ii. Hb \\\u003C 110 g\u002FL AND iii. Platelet count \\\u003C 100 x 109\u002FL\n\n   b. Marked bilineage cytopenia, with two or more of the following present: i. ANC \\\u003C 1.0 x 109\u002FL ii. Hb \\\u003C 110 g\u002FL iii. Platelet count \\\u003C 100 x 109\u002FL\n\n   Note: People with possible CH, with the above characteristics will be excluded from referral to the CH clinic and will instead have urgent investigation as an inpatient or in the haematology clinic. However, if no definite cause for cytopenia is identified, including CH, then individuals may be referred for CH screening at the CH clinic the discretion of the study PI","55 Years",{"count":52,"type":20},100,"5 Years","OBSERVATIONAL","People identified to have CH or thought to have possible CH due to unexplained low blood cell counts, including low red blood cells, white blood cells, or platelets will be asked to take part in the study.\n\nIndividuals who are confirmed to have CH and provide informed consent to participate in the study will have monitoring of their CH, assessment of the risk of heart diseases, blood cancers and personalised support. The researchers will also measure people's understanding of CH and how they feel after learning about CH.\n\nResearchers will then record the relevant information from people with CH in a central database over time to track long-term health outcomes.\n\nThe information collected from the study will help create a blueprint for doctors to provide care for people with CH in the future, and guide further research into CH in Australia.\n\nParticipants will be asked to donate blood samples for the study for research purposes including CH monitoring and testing and also provide health information for the central database.",[26,57,58],"CCUS Clonal Cytopenia of Undetermined Significance","Hematologic Disease and Disorders",[26,60,61],"CH","CCUS","2026-05-11",{"date":64,"type":33},"2026-05-13",{"date":66,"type":33},"2026-03-20",{"date":68,"type":20},"2033-11",{"name":70,"class":71},"Clinical Hub for Interventional Research (CHOIR)","OTHER_GOV",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100493467","a-study-about-how-blood-cell-growth-patterns-relate-to-heart-health-after-treatment-for-hodgkin-lymphoma-100493467","NCT05705531","A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma","Assessment of Clonal Hematopoiesis and Its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors","Inclusion Criteria:\n\n* Patient must be \\>= 7 years of age at the time of enrollment (age to perform an MRI without sedation).\n* History of pathologically confirmed classical Hodgkin Lymphoma (cHL) initially diagnosed when the patient was \\>= 2 and \\\u003C 22 years of age.\n* As part of frontline therapy for cHL, the patient must have received a cumulative doxorubicin equivalent anthracycline dose of ≥ 200 mg\u002Fm\\^2 as estimated in doxorubicin isotoxic equivalents dose conversion calculation.\n\n  * Note: History of COG therapeutic trial participation is not required. Institutional records (e.g., clinic note, treatment summary, chemotherapy roadmap) can be used as reference documentation of receipt of anthracycline dose.\n* All systemic cancer treatment must have been completed ≥ 2 years prior to study enrollment.\n* Not known to have had a primary event (relapse\u002Fsecond malignancy\u002Fdeath).\n\n  * Note: Subjects treated at another institution are eligible if they are now being followed at the current COG institution, if the study procedures can be performed and the data accessible by a COG institution where the study is open.\n* Patient must have access to cardiac MRI at the enrolling institution and must be able to complete cardiac MRI without sedation.\n\nExclusion Criteria:\n\n* Medical contraindication to undergoing a non-contrast cardiac MRI.\n* Patients with nodular lymphocyte-predominant HL.\n* Received cancer therapy in addition to that for primary Hodgkin Disease (e.g., for disease progression or recurrence, or subsequent malignant neoplasm).\n* History of CTCAE grade 3 or higher cardiovascular disease or condition known to exist prior to the patient's initial diagnosis of cHL.\n\n  * Note: exceptions are made for congenital conditions considered fully resolved by surgery and chronic conditions such as hypertension or hypercholesterolemia that are managed with medical intervention.\n* History of an immunodeficiency that existed prior to cHL diagnosis, such as primary immunodeficiency syndromes, organ transplant recipients and conditions requiring systemic immunosuppressive agents.","7 Years",{"count":82,"type":20},190,"This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.",[85,86,26],"Cardiovascular Disorder","Classic Hodgkin Lymphoma","2026-05-01",{"date":89,"type":33},"2026-05-05",{"date":91,"type":33},"2023-08-18",{"date":93,"type":20},"2028-10-01",{"name":95,"class":96},"Children's Oncology Group","NETWORK",32,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":72},"100538832","clonal-hematopoiesis-and-therapy-emergent-myeloid-neoplasms-in-patients-with-cancers-chances-study-100538832","NCT06295965","Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study","Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)","Inclusion Criteria:\n\n* Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:\n\n  * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy\n\nOR\n\n* Subjects who have or have had a solid tumor diagnosis and any of the following:\n\n  * At least 4 months of exposure to a PARP inhibitor\n  * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm\n\nExclusion Criteria:\n\n* Individuals with a life expectancy of less than 6 months",{"count":106,"type":20},2000,"This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is\u002Fare a genetic\u002Fenvironmental component(s) to developing blood cancer.",[109,110,111,112,113,26,114,115,116,117],"Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Malignant Solid Neoplasm","Clonal Cytopenia of Undetermined Significance","Idiopathic Cytopenia of Undetermined Significance","Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder","Ovarian Carcinoma","Myeloid Neoplasm Post Cytotoxic Therapy","2026-04-14",{"date":120,"type":33},"2026-04-17",{"date":122,"type":33},"2024-01-02",{"date":124,"type":20},"2031-12-31",{"name":126,"class":40},"University of Washington",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":135,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100404078","li-fraumeni--tp53-lift-up-understanding-and-progress-100404078","NCT04541654","Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress","Li-Fraumeni & TP53: Understanding and Progress (LiFT UP)","LiFT_UP","Inclusion Criteria:\n\n* Individuals with a TP53 pathogenic or likely pathogenic variant identified in blood or saliva,\n* Individuals with variants of uncertain significance in TP53 may be eligible at the PI's discretion,\n* Blood relatives of individuals with a TP53 variant, who may be presumed obligate carriers or healthy controls,\n* Individuals who meet Classic or Chompret LFS criteria whether or not they have a TP53 gene variant,\n* Individuals may enroll their deceased relatives in the study.\n* Individuals with a known TP53 variant that is not LFS, but rather ACE, CHIP, or mosaicism.\n* Individuals participating in other LFS studies can still enroll in LiFT UP. Investigators may be collaborators.\n\nExclusion Criteria:\n\n* Individuals who decline to sign consent\n* Individuals who are unable to give consent or assent and are without a designated healthcare proxy",{"count":136,"type":20},1500,"The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE\u002FCHIP and mosaicism).",[139,140,141,26,142],"Li-Fraumeni Syndrome","TP53 Gene Mutation","Hereditary Cancer Syndrome","Mosaicism",[139,144,141,26,142],"TP53 Gene Mutation (Variant)","2026-03-24",{"date":147,"type":33},"2026-03-27",{"date":149,"type":33},"2020-09-15",{"date":151,"type":20},"2032-12-31",{"name":153,"class":40},"Dana-Farber Cancer Institute",3,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":167,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":177,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":154},"100626438","phase-2-modulation-of-stem-cell-differentiation-in-individuals-with-high-risk-clonal-haematopoiesis-100626438","NCT07435636","Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis","A Multi-centre, Double-blind, Placebo-controlled Randomised Phase II Trial to Evaluate the Effect of Low Dose Decitabine and Tetrahydrouridine in Individuals With High-risk Clonal Haematopoiesis","MOSAIC","Inclusion Criteria:\n\n1. Age ≥ 60 and ≤ 85 years old\n2. Clonal Cytopenia of Uncertain Significance (CCUS), defined by all of the following:\n\n   a. Persistent cytopenia, present on at least two occasions, at least four months apart, with no other cause identified: i. Hemoglobin (Hb) \\\u003C 120 g\u002FL in people born female, and \\\u003C 130 g\u002FL in people born male ii. Platelet count \\\u003C 150 x 109\u002FL iii. Absolute Neutrophil Count (ANC) \\\u003C 1.8 x109\u002FL b. Clonal hematopoiesis (CH) driver mutation confirmed by custom gene panel mutation analysis c. absence of features diagnostic for defined myeloid neoplasm (MN) on bone marrow examination\n3. CH driver mutation variant allele fraction (VAF) of ≥ 10%\n4. For participants living with HIV:\n\n   1. Receiving and adherent to suppressive antiretroviral therapy for at least 12 months\n   2. CD4+T cell count ≥ 0.35 x 109\u002FL\n   3. HIV viral load \\\u003C 50 copies\u002FmL\n\n6\\. Performance status by Eastern Cooperative Oncology Group (ECOG) Criteria of 0 or 1 7. For participants who are of childbearing potential, or whose partners are of childbearing potential:\n\n1. Agreement to use at least two highly effective (per Clinical Trial Facilitation Group) contraceptive methods throughout the course of the trial, and for 6 months following the last dose of trial drug\n2. Refrain from donating eggs or sperm during the same period\n3. Confirmation of a negative serum pregnancy test at screening and at the beginning of each treatment cycle visit (for female participants of childbearing potential) 8. Provision of signed written informed consent document prior to any trial-related assessments or procedures being carried out\n\nExclusion Criteria:\n\n1. ANC \\\u003C 0.5 x109\u002FL\n2. Serum AST (Aspartate transaminase) or ALT (Alanine aminotransaminase) \\> 3 times of upper limit of normal\n3. Calculated or measured creatinine clearance ≤ 50 mL\u002Fmin\n4. Significant active cardiac disease within the previous 6 months, including:\n\n   1. New York Heart Association (NYHA) class III or IV congestive heart failure\n   2. Unstable angina or angina requiring surgical or medical intervention\n   3. Myocardial infarction\n   4. New or unstable cardiac arrhythmia. Stable or controlled arrhythmias are permitted\n5. Active systemic infections:\n\n   1. Infection with ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate anti-infectives\n   2. Active Hepatitis B infection (HBV) (defined as HBsAg positive, or HBcAb positive and measurable HBV DNA; participants who are HBcAb positive must have HBV DNA assayed during screening)\n   3. Active Hepatitis C Virus (HCV) will be ineligible if there is clinical hepatic dysfunction or other systemic manifestations of HCV disease, or if the hepatic eligibility parameters above are not met. Consideration should be given to curative HCV therapy prior to enrolment in consultation with HCV clinician\n6. Any history of hematological or solid malignancy in previous the 5 years unless the participant has been free of disease for ≥ 36 months. However, participants with the following history\u002Fconcurrent conditions are not excluded:\n\n   1. Basal or squamous cell carcinoma of the skin\n   2. Carcinoma in situ of the cervix\n   3. Carcinoma in situ of the breast\n   4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis \\[TNM\\] clinical staging system)\n7. Known hypersensitivity to trial drugs or their constituents\n8. Currently enrolled in the treatment phase of an interventional investigational trial.\n9. Pregnant or breast-feeding individuals\n10. Any condition not already outlined above which, in the opinion of the Principal Investigator, would place the participant at risk if they participated or would jeopardize adherence, follow up, or confound the ability to interpret trial data","60 Years","85 Years",{"count":166,"type":20},80,[168],"PHASE2","Clonal hematopoiesis (CH) is characterized by the overproduction of blood cells derived from a single hematopoietic stem and progenitor cell (HSPC) harboring certain somatic mutations. It is linked to serious outcomes, including cardiovascular disease, myeloid neoplasm (MN), and increased mortality.\n\nClonal Cytopenia of Uncertain Significance (CCUS) is a CH subtype characterized by associated persistent cytopenia. It affects approximately 10 % of people over 70 and is the most advanced precursor state with the highest risk of progressing to MN. There is an unmet need to determine whether modifying CH can prevent adverse outcomes. Current blood cancer therapies are too toxic for precursor conditions like CH.\n\nMOSAIC is a randomized double-blind placebo-controlled trial that will test a novel low-dose oral epigenetic therapy-decitabine with tetrahydrouridine (Dec+THU) in CCUS. It has shown targeted, non-cytotoxic reversal of common CH mutations in preclinical and early-phase studies.\n\nThe goal is to develop a safe and effective therapy in CCUS that restores normal blood cell production and prevents progression.",[171,57,26],"Clonal Cytopenia of Uncertain Significance",[161,60,173,61,174,175,176,171],"Modulation of stem cell differentiation","persistent cytopenia","clonal hematopoiesis","clonal haematopoiesis","NOT_YET_RECRUITING","2026-02-23",{"date":180,"type":33},"2026-02-27",{"date":182,"type":20},"2026-04-13",{"date":184,"type":20},"2030-10",{"name":70,"class":71},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":194,"targetDuration":196,"studyType":54,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":72},"100569974","the-clonal-hematopoiesis--inflammation-in-vasculature-registry-and-biorepository-100569974","NCT06701214","The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository","Discovering Outcomes in Clonal Hematopoiesis: The Clonal Hematopoiesis and Inflammation in VasculaturE (CHIVE) Registry and Biorepository","CHIVE","Inclusion Criteria:\n\n* Patient greater than or equal to 18 years old at time of consent\n* Able to provide informed consent\n* Idiopathic cytopenia (ICUS) or idiopathic cytoses (elevated blood counts without disease or explanation); clonal cytopenia of undetermined significance (CCUS), clonal hematopoiesis of indeterminate potential (CHIP) or individuals at higher risk for clonal hematopoiesis (ex. patients with known diagnosis of solid tumors or cardiovascular disease)\n\nExclusion Criteria:\n\n* Unable to provide consent\n* Diagnosis of active hematologic malignancy. For example, a diagnosis of CMML, AML, MDS, MPN; History of hematologic malignancy is NOT exclusionary if in complete remission (e.g. previous myeloma or lymphoma)",{"count":195,"type":20},800,"10 Years","This study will investigate the association between clonal hematopoiesis and other conditions. Clonal hematopoiesis (CH) refers to the mutations in a person's stem cells which commonly affect people as they get older. These mutations have notably been linked to increased risk of certain cancers as well as increased risk of heart disease.",[26],"2024-11-20",{"date":201,"type":33},"2024-11-22",{"date":203,"type":33},"2020-10-28",{"date":205,"type":20},"2031-11-30",{"name":207,"class":40},"Vanderbilt-Ingram Cancer Center",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":72},"100415447","donor-chip-and-allogeneic-hsct-outcome-100415447","NCT04689750","Donor CHIP and Allogeneic HSCT Outcome","Impact of Donor Clonal Haematopoiesis of Indeterminate Potential (CHIP) on Recipient Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (Allo-HSCT)","Inclusion Criteria:\n\n1. Adult aged 18 year or above\n2. Donor and recipient of allo-HSCT\n3. In prospective and partial prospective\u002Fretrospective case, subjects who have provided a signed written informed consent. In retrospective case, subjects who had provided a previously signed written informed consent on:\n\n   1. voluntary provision of clinical data, and\n   2. voluntary provision of archived\u002Fremaining specimens for genetic analysis, and\n   3. authorizing storage and usage of archived\u002Fremaining specimens for any further analysis\n\nExclusion Criteria:\n\n1\\. Autologous peripheral blood stem cells or bone marrow stem cell donors for autologous HSCT",{"count":216,"type":20},850,"Current data on the impact of donor CHIP on long-term recipient outcome remain largely speculative. Data on the impact of donor CHIP including on allograft function, immunologic dysfunction, graft versus host disease (GVHD), disease relapse and survival across various donor populations are scarce. This is a retrospective-prospective cohort study designed to determine the association between donor gene mutations and outcome following allogeneic HSCT.",[26],[220,221,222],"Donor clonal hematopoiesis","Allogeneic hematopoiectic stem cell transplantation","Outcome","2022-10-03",{"date":225,"type":33},"2022-10-04",{"date":227,"type":33},"2021-01-01",{"date":229,"type":20},"2026-12-31",{"name":231,"class":40},"The University of Hong Kong"]